DART trial: Immune checkpoint combo shows promise for high-grade neuroendocrine carcinoma
4 Views
administrator
07/09/23
Dual immune checkpoint blockade with ipilimumab and nivolumab was well tolerated in patients with neuroendocrine cancer and showed particular efficacy in those with high-grade tumors, according to findings from a prospective, open-label, phase 2 basket trial. Dr. Sandip Pravin Patel discusses the results. Learn more at www.mdedge.com.
Show more
Facebook Comments
No comments found